Xilio Therapeutic announced initial clinical data from its ongoing Phase 1C clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with advanced solid tumors. The data will be presented in a late-breaker poster presentation on November 8, 2024, at the Society for Immunotherapy of Cancer, SITC, 39th Annual Meeting taking place in Houston, Texas.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter